Opus Genetics Inc. has entered into a significant funding agreement with the Foundation Fighting Blindness Retinal Degeneration Fund $(RDF.AU)$ to advance their MERTK gene therapy program for retinitis pigmentosa. Announced on June 13, 2025, the agreement will provide Opus Genetics with up to $2 million in nondilutive funding from RDF, with an initial $1 million to be disbursed shortly and an additional $1 million contingent upon achieving specified development milestones. This collaboration marks a crucial step in developing therapies for patients affected by pathogenic variants in the MERTK gene. The agreement outlines Opus Genetics' obligations to diligently progress and commercialize the program, with potential milestone and royalty payments to RDF. In case of a change in company control or a sale, RDF holds an option for a buyout of its interest. This partnership underscores the collaborative efforts between Opus Genetics and RDF in addressing retinal degenerative diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.